Effects of general anesthesia combined with oxybuprocaine hydrochloride eye drops on oculocardiac reflex, agitation and pain during recovery period during strabismus surgery in children

Start Date23 Mar 2026

Sponsor / Collaborator

Ningxia Hui Autonomous Region People's Hospital

CTIS2024-516232-10-00

/ Not yet recruitingPhase 4IIT

Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

Start Date01 Dec 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

CTR20252513

/ RecruitingNot Applicable

妥布霉素吸入溶液长期给药方案治疗支气管扩张症伴铜绿假单胞菌感染患者中血清及肺内药物浓度及药代动力学/药效学与疗效评价研究

[Translation] Study on serum and lung drug concentrations, pharmacokinetics/pharmacodynamics and efficacy evaluation of long-term administration of tobramycin inhalation solution in the treatment of bronchiectasis patients with Pseudomonas aeruginosa infection

1) 评价妥布霉素吸入溶液在支气管扩张症（支扩症）伴铜绿假单胞菌（PA）感染患者中多次用药后在肺上皮衬液（ELF）和血清中的药物浓度及ELF到血液的渗透性； 2) 评价妥布霉素吸入溶液长疗程（12周）给药方案，治疗支扩症伴PA感染患者的细菌学指标变化； 3) 研究妥布霉素吸入溶液在支扩症伴PA感染患者中多次用药后的药代动力学（PK）/药效学（PD）与疗效相关性。

[Translation]

1) To evaluate the drug concentration of tobramycin inhalation solution in pulmonary epithelial lining fluid (ELF) and serum and the permeability of ELF to blood after multiple administration in patients with bronchiectasis (bronchiectasis) and Pseudomonas aeruginosa (PA) infection; 2) To evaluate the long-term (12-week) dosing regimen of tobramycin inhalation solution to treat the changes in bacteriological indicators in patients with bronchiectasis and PA infection; 3) To study the pharmacokinetics (PK)/pharmacodynamics (PD) and efficacy correlation of tobramycin inhalation solution in patients with bronchiectasis and PA infection after multiple administration.

Start Date10 Oct 2025

Sponsor / Collaborator

Healthy Yuan Haibin Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Tobramycin

100 Translational Medicine associated with Tobramycin

100 Patents (Medical) associated with Tobramycin

11,391

Literatures (Medical) associated with Tobramycin

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Comparison the effect of Curcumin and methanolic extracts of Fraxinus excelsior L. and glycyrrhiza glabra L. on the expression of MexCD-OprJ and MexEF-OprN efflux pumps in multidrug resistant Pseudomonas aeruginosa clinical isolates

Article

Author: Goli, Hamid Reza ; Gholami, Mehrdad ; Jamal, Zeynab ; Ebrahimzadeh, Mohammad Ali

BACKGROUND:

Pseudomonas aeruginosa is a multidrug-resistant (MDR) pathogen, and efflux pumps such as MexCD-OprJ and MexEF-OprN play a key role in its antibiotic resistance. This study evaluated the putative effects of curcumin and methanolic extracts of F. excelsior L. and G. glabra L. on the expression of these efflux pumps, as well as their role in mediating antibiotic resistance.

METHODS AND RESULTS:

In this study, MDR P. aeruginosa clinical strains were used to determine the minimum inhibitory concentrations (MICs) of tobramycin and ciprofloxacin in the presence and absence of curcumin and selected plant extracts (F. excelsior L. and G. glabra L.) and curcumin. Real-time PCR was used to assess changes in efflux pump gene expression in tested strains. A significant positive correlation was identified between resistance to the tested antibiotics and increased expression of MexCD-OprJ and MexEF-OprN, as determined by Spearman's rank correlation using SPSS (p < 0.05). Treatment with the extracts, individually and in combination, resulted in a reduction in the expression levels of both efflux genes (p < 0.05), with the combined treatment showing the greatest effect. These findings were supported by colony count and turbidity assays, as evidenced by > 80% reduction in viable counts and decreased turbidity in treated groups.

CONCLUSION:

Overexpression of MexCD-OprJ and MexEF-OprN is a key factor contributing to MDR in P. aeruginosa. Treatment with curcumin, F. excelsior L. and G. glabra L. extracts-especially in combination, suggesting potential for suppression of efflux gene expression and enhanced antibiotic efficacy.

01 Dec 2026·FUNCTIONAL & INTEGRATIVE GENOMICS

An integrated computational-experimental approach identifies Malate Synthase G as therapeutic target to disrupt carbon metabolism in chronic Pseudomonas aeruginosa infection

Article

Author: Wang, Rui ; Mo, Jingyi ; Xu, Jun ; Chen, Geping ; Chen, Wenying ; Zhou, Haochuan ; Tan, Qiutong

Pseudomonas aeruginosa is a leading cause of nosocomial infections, particularly in individuals with a compromised immune system. Due to its strong adaptive ability, P. aeruginosa tends to develop antibiotic resistance and establish chronic infection, making its eradication through traditional antibiotics challenging. Thus, the development of novel therapeutic targets and corresponding inhibitors is urgently required. We conducted bioinformatics analyses of gene-chip datasets (GSE10362, GSE21966) of P. aeruginosa from patients with cystic fibrosis (CF) in the Gene Expression Omnibus (GEO) database, ranging from early to late stages of infection. Differentially expressed gene (DEG) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, and Weighted Gene Co-expression Network Analysis (WGCNA) were performed to identify key functional DEGs. Among these genes, candidate genes were refined using three machine learning algorithms: LASSO regression, random forest (RF), and support vector machine (SVM). Using this integrated approach and published reports, target gene was identified consequently. With reported inhibitors, a structure-based virtual screening model against the target protein was established to screen inhibitors from an FDA-approved drug library. Screened hits were experimentally validated through in vitro MIC and checkerboard broth microdilution assays to determine their antibacterial activity and the synergistic effect of tobramycin (TOB) and amikacin (AMK). Enzyme activity was measured to evaluate target protein inhibition. Transcriptome sequencing analysis was performed to explain the effect of target inhibition and reveal the possible mechanism of inhibition. We identified 210 upregulated genes in the late stage of infection. KEGG functional enrichment demonstrated that the up-regulated genes were mainly enriched in metabolic pathways. Eight metabolism-related key DEGs were obtained by the intersection of genes from metabolic pathways and genes from the key module of WGCNA. Machine learning algorithms (LASSO, RF, and SVM) and literature investigation results identified glcB, which encodes malate synthase G (MS), as a therapeutic target for developing inhibitors. In virtual screening, we formulated four rules for a screening model based on the docking results, and finally identified three FDA-approved drugs prednisolone, dienogest and carbinoxamine maleate salt (CAR) as candidates. In vitro MIC assay and checkerboard assay suggested that CAR had an antibacterial effect with a concentration-dependent trend and could enhance the effect of tobramycin and amikacin. Consistent with MIC assay, the inhibition rate in MS activity assay showed a concentration-dependent trend. Transcriptome sequencing analysis showed that carbon metabolism was remodeled when MS was inhibited, thus impairing the growth of P. aeruginosa, and the synergistic effect with TOB and AMK may be explained by the impaired ability to combat oxidative stress. This study identified and validated drug target glcB (encodes MS) and potential inhibitor CAR in treating chronic P. aeruginosa infection based on an integrated method of bioinformatics, virtual screening, and in vitro experiments.

01 Oct 2026·FREE RADICAL BIOLOGY AND MEDICINE

Gentamicin triggers fatty acid oxidation–dependent mitochondrial ROS, driving greater nephrotoxicity than apramycin and other aminoglycosides

Article

Author: Cirule, Helena ; Hobbie, Sven N ; Dambrova, Maija ; Liepinsh, Edgars ; Sevostjanovs, Eduards ; Makrecka-Kuka, Marina ; Ozola, Melita ; Pinkovskis, Kristaps ; Krims-Dāvis, Kristaps

Apramycin has emerged as a promising antibacterial drug candidate that has demonstrated great preclinical efficacy and safety profile. In comparative studies, apramycin was found to be significantly less nephrotoxic than gentamicin; however, the underlying mechanisms have not been clarified. In the present study, we investigated whether different aminoglycoside antibiotics share the same toxicity mechanisms and whether cotreatment with the antioxidant N-acetyl-cysteine (NAC) can ensure even safer apramycin use. In addition, we investigated whether cilastatin decreases apramycin content in the kidneys and thus mitigates adverse effects. We found that NAC in combination with apramycin was not beneficial; a similar or even greater increase in nephrotoxicity markers was observed with this combination in rats and mice. Furthermore, we found that only gentamicin and, to a lesser extent, arbekacin and kanamycin induced a prominent increase in the mitochondrial fatty acid oxidation (FAO)-dependent production of H₂O₂. Apramycin, paromomycin, neomycin, dibekacin, geneticin, amikacin, tobramycin, and plazomicin stimulated neither FAO nor H₂O₂ production in kidney mitochondria. We also found that gentamicin C1, which is one of the congeners in clinically used gentamicin, did not increase mitochondrial FAO or related H₂O₂ production. In rats, treatment with cilastatin combined with apramycin partially prevented glomerular but not tubular kidney damage induced by a high dose of apramycin. In the same animals, we found that cilastatin did not affect apramycin content in the kidneys. In conclusion, gentamicin differs from other aminoglycoside antibiotics by coupling fatty-acid oxidation to mitochondrial reactive oxygen species (ROS) generation. Gentamicin congener C1, apramycin, and 10 other tested aminoglycosides do not stimulate mitochondrial ROS production, and the use of antioxidants to protect the kidneys against these aminoglycosides is not a reasonable strategy. Cilastatin protects against aminoglycoside-induced glomerular damage independent of the inhibition of aminoglycoside transport into kidney cells.

News (Medical) associated with Tobramycin

14 Jul 2026

·www.biospace.com

Sound Pharma completes enrollment of Open Label Phase 3 study of SPI-1005 in Meniere’s Disease

SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD). SPI-1005, a novel oral anti-inflammatory drug, received Breakthrough Therapy Designation (BTD) in late 2025. MD is a complex inner ear disease that involves low to mid frequency hearing loss, tinnitus, vertigo, and dizziness. SPI-1005 is the first drug to receive BTD for MD and for the treatment of sensorineural hearing loss, the most prevalent disease involving the nervous system. Sensorineural hearing loss is documented using pure-tone audiometry (PTA) and speech discrimination testing including the words-in-noise (WIN) test that are the gold standards for diagnosing and grading hearing loss and other auditory dysfunction. “We look forward to advancing SPI-1005 as the first approved treatment for Meniere’s later this year and early next year,” said Dr. Jonathan Kil, Co-Founder and CEO. This open label Phase 3 study was performed to accrue additional safety data to allow for chronic daily dosing of SPI-1005 and enrolled 191 participants at 9 US sites in 8 months’ time. The four MD trials have now enrolled a total of 578 adults with probable or definite Meniere’s. To our knowledge, this represents the greatest number of MD participants enrolled in an investigational new drug trial over the last 10 years. SPI-1005 trials have also achieved favorable safety and efficacy results in a Phase 2 RCT in acute noise-induced hearing loss, and a Phase 2 RCT in aminoglycoside-induced ototoxicity. About SPI-1005 SPI-1005, an oral capsule taken twice daily contains ebselen, a new chemical entity that mimics and induces glutathione peroxidase (GPx) activity. GPx1 is a critical enzyme that repairs injured and aging cells in the inner ear, retina, prefrontal cortex of brain, lung, and kidney, and is reduced during and after exposure to environmental insults such as noise, ototoxic drugs, or aging. Consequently, neuroinflammation can progress throughout the peripheral and central nervous system leading to neurodegeneration and/or maladaptive plasticity. SPI-1005 is being developed for several neurotologic indications beyond MD including, noise-induced hearing loss and tinnitus, and two types of ototoxicity (hearing loss, tinnitus, dizziness, or vertigo) caused by aminoglycoside antibiotics (such as tobramycin or amikacin) or platinum-based chemotherapy (such as cisplatin or carboplatin). To date, no significant drug-drug interactions have been observed across multiple study populations including MD, cystic fibrosis, bipolar mania, and treatment-resistant depression. Fifteen ongoing and completed SPI-1005 trials have enrolled more than 980 patients with 200+ more enrolled patients anticipated over the next year. About Sound Pharmaceuticals Sound Pharma is a private biotechnology company studying SPI-1005 under five active INDs involving several neurotologic indications. Details of the SPI-1005 clinical trials can be viewed online at or . Please contact info@soundpharma.com for further information. Contacts Please contact info@soundpharma.com for further information.

19 May 2026

·www.biospace.com

Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board

Industry leaders join at a pivotal moment as company advances HT-6184 toward a pivotal trial in MDS and prepares Phase 2a initiation for HT-4253 in Alzheimer's disease LEHI, Utah , May 19, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., The Genetic Resilience Company™ , a clinical-stage biopharmaceutical company advancing first-in-class inflammation therapies anchored in protective human genetics, today announced the appointment of Gary Sabin as Executive Chairman of the Board of Directors. Mr. Sabin has been a member of Halia's Board of Directors since January 2025. The company also announced the additions of Preston Campbell, MD, David Checketts, and Mary Beckerle, PhD, as independent members of the board. The expanded board joins Halia at a defining moment for the company, as it advances HT-6184 toward pivotal development in lower-risk myelodysplastic syndromes and continues to build its broader pipeline across inflammation-driven diseases. Earlier this month, Halia announced final Phase 2 data for HT-6184 in lower-risk MDS, as well as the appointment of Han Myint, MD, FACP, as Chief Medical Officer, further strengthening the company's clinical and leadership foundation for its next phase of growth. "We are pleased to formally expand Gary's leadership role to Executive Chairman and to welcome Preston, David, and Mary to the board," said David J. Bearss, PhD, Chief Executive Officer of Halia Therapeutics. "Since joining our board in January 2025, Gary has been a highly engaged strategic partner, and his experience in capital markets, governance, and company-building has already contributed meaningfully to Halia's growth. Together with the additions of Preston, David, and Mary and following the recent advancement of our lower-risk MDS program and appointment of Dr. Han Myint as Chief Medical Officer, we are continuing to strengthen the leadership, scientific and strategic capabilities needed to advance HT-6184 toward pivotal development, expand our pipeline and support the company's next phase of growth, financing and partnering." "Halia's platform is the rare combination of a clear, genetically validated mechanism and clinical data that already supports its potential," said Gary Sabin, Executive Chairman. "Over the past year, I have had the opportunity to work closely with David, the leadership team, and the board, and I am excited to deepen that engagement as Executive Chairman, while helping build the company for long-term success." About the New Directors Gary B. Sabin — Executive Chairman Gary B. Sabin joined Halia's Board of Directors in January 2025 and now serves as Executive Chairman, bringing more than four decades of leadership in capital markets and asset-intensive businesses. He previously served as Chairman and CEO of Excel Realty Trust and Excel Trust, both of which were listed on the New York Stock Exchange, and is founder and chairman of Sabin Holdings, an Asia-Pacific-focused real estate investment firm. He has served on the boards of public companies including CareTrust REIT and Extra Space Storage and nonprofits including the Cystic Fibrosis Foundation, where he served for 20 years, including as Vice Chairman of the Board and Chairman of the Executive Committee. During his tenure, the Foundation was instrumental in facilitating FDA approval of several new therapies, including the disease-modifying drug Trikafta, as well as Tobi, Pulmozyme, Symdeko, Orkambi, Kalydeco, and Cayston. He holds a Master's in Management from Stanford University (Sloan Fellow) and a BS in Finance from Brigham Young University. At Halia, Mr. Sabin brings capital markets perspective, public-company governance experience, and executive discipline, and is working closely with leadership on financing, strategy, and growth. Preston W. Campbell III, MD Preston W. Campbell III, MD, is a physician-executive and former President and CEO of the Cystic Fibrosis Foundation (2015–2019). Dr. Campbell brings to Halia clinical development, patient-registry, and translational medicine experience aligned with the company's genetically informed pipeline. Over more than two decades at the Foundation, including as EVP for Medical Affairs, he oversaw research, drug discovery and development, the accredited care-center network, and the national patient registry, infrastructure behind many of the pivotal studies in cystic fibrosis. He trained in pediatrics and pediatric pulmonology at Vanderbilt and has more than 25 years of clinical experience in cystic fibrosis at institutions, including Johns Hopkins. David W. Checketts David W. Checketts is a veteran chief executive and investor with more than four decades of experience across sports, media, entertainment, and private equity. Mr. Checketts adds brand-building, governance, and capital formation experience as Halia transitions to a growth-stage organization. He became president and general manager of the Utah Jazz at age 28, then the youngest chief executive in NBA history, and later served as President and CEO of Madison Square Garden, overseeing its sports franchises and media networks. He subsequently served as Chairman and CEO of Legends Hospitality, managing partner of Checketts Partners Investment Management, and was a founding board member of JetBlue Airways. Mary C. Beckerle, PhD Mary C. Beckerle, PhD, is a cancer biologist and scientific leader who served as CEO of Huntsman Cancer Institute (2006–2025). She is Distinguished Professor of Biology and Oncological Sciences at the University of Utah. She joined the University of Utah faculty in 1986 and is recognized for pioneering research on cell adhesion, migration, invasion, and metastasis. She serves on the boards of Johnson & Johnson and Exelixis, is an elected member of the National Academy of Sciences, and has served on the Advisory Committee to the Director of the National Institutes of Health. The new directors join existing board members Keoni Kauwe, PhD, Co-founder, and David J. Bearss, PhD, Chief Executive Officer. About Halia Therapeutics Halia Therapeutics is a clinical-stage platform company focused on inflammation biology. The company's platform is anchored in protective human genetics that identified the LRRK2 -> RAB10 -> NEK7 -> NLRP3 axis as a source of human disease resilience. Halia is translating that biology into a pipeline of first-in-class programs, including HT-6184 in lower-risk myelodysplastic syndromes and additional hematologic indications, HT-4253 for Alzheimer's disease in APOE4 carriers, HT-6105 targeting residual inflammatory risk via hsCRP reduction, and HT-10068 for metabolic disease. To learn more, visit haliatx.com . Contacts Taylor Avei Director of Business Development Halia Therapeutics tavei@haliatx.com Investor Relations: Leigh Salvo New Street Investor Relations leigh@newstreetir.com View original content to download multimedia: SOURCE Halia Therapeutics

Executive ChangePhase 2Drug Approval

18 Mar 2026

·allsci.com

HCW Biologics hands Phase I development of tri-specific fusion immunotherapeutic to China’s Trimmune

HCW Biologics Inc. (NASDAQ: HCWB), a Florida-based biopharma, has closed an exclusive worldwide license for HCW11-006, a preclinical fusion immunotherapeutic, signed with Beijing Trimmune Biotech Co., Ltd. Trimmune is a newly formed entity established by WY Biotech Co., Ltd., a China-based recombinant protein and gene/cell therapy developer, and HCW Biologics. The license deal grants Trimmune rights to develop and commercialize HCW11-006 globally, with a Phase I clinical study in China expected in the first half of 2027. Trimmune will bear all costs associated with that trial, as per the deal announcement. The deal terms include an upfront payment of USD 7.0 million, comprised of USD 3.5 million in cash and USD 3.5 million of equity in Trimmune. HCW Biologics is also eligible for development milestone payments along with double-digit royalties on future product sales. The company is further entitled to a portion of proceeds from any future transactions involving the licensed molecule. Financial terms beyond these categories were not disclosed. Trimmune’s investors include CITIC Medical Fund and TigerYeah Capital Fund of TigerMed. A structural element of this immunotherapy licensing deal is a payment-free, milestone-free, and royalty-free option retained by HCW Biologics to recapture all rights for in vivo applications of HCW11-006 in the United States, Canada, Central America, and South America. That option becomes exercisable after the conclusion of the Phase I clinical trial in China. This provision means HCW Biologics could regain the Americas territory without additional cost, using Trimmune-funded Phase I data to inform its decision. The deal also provides Trimmune with an option to license exclusive regional China rights to HCW9302, a separate clinical-stage molecule from HCW Biologics currently in a Phase I study in alopecia areata (NCT07049328). Deal context HCW11-006 is a multi-functional fusion protein biologic generated from HCW Biologics’ proprietary TRBC drug discovery and development platform. The company has stated it has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-018, and HCW11-040, though clinical details on those assets have not been disclosed. HCW Biologics HCW11-006 is designed to integrate functional domains of interleukin-12, interleukin-15, and a PD-L1 blocking component into a single engineered construct. The molecule is intended to simultaneously activate natural killer cells and T cells through cytokine receptor signaling while blocking the PD-1/PD-L1 immune checkpoint axis. No clinical trials for HCW11-006 are currently registered on clinicaltrials.gov. The asset remains in preclinical development. The HCW Biologics exclusive license agreement fits within the company’s stated strategy of using business development to finance clinical programs. HCW Biologics operates a second platform, TOBI, which generated HCW9302 and HCW9218, a fusion protein that has been in a Phase 1b study in advanced pancreatic cancer. The TRBC platform, from which HCW11-006 originates, is focused on multi-specific immunotherapeutic molecules, including second-generation T-cell engagers designed for solid tumors. Several companies are developing engineered cytokine therapies and immunocytokines targeting similar immune activation pathways. These include bifunctional cytokine constructs such as Sonnet BioTherapeutics’ IL-12/IL-15 fusion, IL-15–based agonists such as ImmunityBio’s approved Anktiva, and conditionally activated cytokine platforms from Werewolf Therapeutics. HCW11-006 differs in that it is designed as a multi-functional fusion protein incorporating cytokine signaling domains alongside checkpoint blockade within a single molecule. This “all-in-one” approach aims to replicate combination immunotherapy effects in a single construct. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 1License out/inImmunotherapyGene Therapy

100 Deals associated with Tobramycin

External Link

KEGG	Wiki	ATC	Drug Bank
D00063	Tobramycin	S01AA12 J01GB01	DB00684

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchiectasis	China	Joincare Pharmaceutical Group Industry Co., Ltd.	11 Oct 2022
Cystic Fibrosis	Japan	Viatris Pharmaceutical GK	28 Sep 2012
Cystic Fibrosis	Japan	Viatris Healthcare GK	28 Sep 2012
Infectious Lung Disorder	European Union	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Iceland	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Liechtenstein	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Norway	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Pseudomonas Infections	United States	Viatris Specialty LLC	22 Dec 1997
Acute Bronchitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Cystitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Hemorrhagic Septicemia	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Peritonitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pneumonia	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pyelonephritis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pyoderma	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Secondary infection	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Blepharitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Conjunctivitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Corneal Ulcer	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Dacryocystitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cataract	Phase 3	United States	Bausch & Lomb, Inc.	01 Feb 2009
Pseudomonas aeruginosa infection	Phase 3	Lithuania	Novartis Pharma Services AG	19 Sep 2005
Eye Infections	Phase 3	United States	Bausch & Lomb, Inc.	01 Jul 2005
Postoperative Complications	Phase 3	United States	Bausch & Lomb, Inc.	01 Jul 2005
Non-cystic fibrosis bronchiectasis	Phase 2	Belgium	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	France	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Germany	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Italy	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Spain	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	United Kingdom	Novartis Pharmaceuticals Corp.	08 Feb 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05865743 (PERSuaDER, Pubmed \| Trials)	Phase 3	Esophageal Carcinoma	854	SDD prophylaxis	vfgnmddtrn(reuhbpheqt) = yhzastsihu nyotwtgmrm (xyhgguhiud )	Positive	04 Dec 2025
ERS2023	Not Applicable	Bronchiectasis	13	Tobramycin inhalation solution (TIS) 170 mg	xfvancnron(hoqpikmlli) = one patient mefonbayrk (lkavpyoswb ) View more	Positive	09 Sep 2023
NCT03705962 (CTgov)	Phase 3	Fractures, Open \| Infectious Diseases	11	Tobramycin (Antibiotic)	yclocyzigw = ocwayoppod ljfzjnxwhx (pjdndeaolq, uqvzgiezip - cpshlzsctr) View more	-	15 Jun 2023
				Placebo: normal saline (Normal Saline)	yclocyzigw = bjrrpctnwp ljfzjnxwhx (pjdndeaolq, ptatentssi - mnsdfecysc) View more
NCT02478710 (AAINTVAP, CTgov)	Phase 4	Pneumonia, Ventilator-Associated	16	Aerosolized Placebo (Aerosolized Placebo)	jczngyywod(bsqlqtkpjl) = elktkrrlwe kmqcgysrvk (ctnqnnuvyc, cbzhsljmol - kavojtzoow) View more	-	22 May 2023
				Tobramycin+Vancomycin (Aerosolized Tobramycin or Vancomycin)	jczngyywod(bsqlqtkpjl) = wpedgjqvmg kmqcgysrvk (ctnqnnuvyc, toulmaxvvx - tjtodrmfbd) View more
NCT02657473 (The BATTLE study, Pubmed \| Respir Res)	Phase 2/3	Non-cystic fibrosis bronchiectasis Maintenance	58	Tobramycin inhalation solution (TIS)	kxscdofjpa(nqddsazbyk): RR = 0.74 (95% CI, 0.49 - 1.14), P-Value = 0.15	-	03 Dec 2022
				Placebo
NCT02918409 (CTgov)	Phase 4	Cystic Fibrosis	51	Colistin (Standard Colistin Arm)	jtcbbmfdbl(kvatnkpzhr) = nhbxwyzekk mjkqwkujcg (duzfdrphly, 9.5) View more	-	06 Oct 2022
				Colistin (Modified Colistin Arm)	jtcbbmfdbl(kvatnkpzhr) = fxvalcbxww mjkqwkujcg (duzfdrphly, 3.0) View more
NCT03673956 (CTgov)	Phase 1/2	Chronic sinusitis	19	Tobramycin (Tobramycin Topical Antibiotic Nasal Saline Rinse)	nyehnvnwup = mwrsaqdrss nzpuheaxsx (gspffbnuqq, lmclojfjyq - cwnfqgizwl) View more	-	20 Apr 2022
				levofloxacin (Levofloxacin Topical Antibiotic Nasal Saline Rinse)	nyehnvnwup = dhcuuhnden nzpuheaxsx (gspffbnuqq, vagmubxxry - tmpgvlbell) View more
NCT04297631 (CTgov)	Phase 4	-	20	Tobramycin+Vancomycin (Intraarticular Concentrations of Tobramycin and Vancomycin)	jdvohslbiv(cznwxfzlsm) = jmaxoqaubh vfmhnportr (hurcipccmh, pynqbpayps - pbiigefjul) View more	-	05 Oct 2021
				Tobramycin+Vancomycin (Vancomycin and Tobramycin Serum Concentration)	bwrdnbhnvm(dxvwlqnkfd) = kzwtlcguoq dmfmbgrzva (bhaeocnrma, abjjgqidvx - eqkcxfcomo) View more
NCT01069705 (CTgov)	Phase 3	Pseudomonas Infections \| Pseudomonas aeruginosa infection \| Cystic Fibrosis ... View more	49	Tobramycin inhalation powder	jmtcszmlcz = kdugedonhi smxcfuaorc (jgncqwtsql, krbsoxfhpz - bpzfrfimwp) View more	-	02 Jun 2021
NCT00982930 (CTgov)	Phase 3	Pseudomonas aeruginosa infection \| Cystic Fibrosis	55	Tobramycin	whokbxbinu = qjlxohirly asyyacrjdf (hfmxtqukiw, hnluhutggh - rmywbzhmdk) View more	-	02 Jun 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis